SCHEDULE: Sofinnova Crossover Sells Abivax Shares

Sofinnova Crossover I SLP and associated individuals have amended their Schedule 13D filing to report the sale of Abivax S.A. American Depositary Shares and Ordinary Shares.

Summary

• Sofinnova Crossover I SLP (SC), along with its management company Sofinnova Partners SAS (SP SAS) and investment committee members Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson, and Jacques Theurillat (collectively, the Reporting Persons), have filed an amendment to their Schedule 13D.
• This amendment details the sale of Abivax S.A. American Depositary Shares (ADSs) and Ordinary Shares in open market transactions between June 30, 2026, and July 3, 2026.
• As of July 6, 2026, SC directly holds 2,474,299 Ordinary Shares, representing approximately 3.1% of Abivax's outstanding Ordinary Shares, and 3,535,843 voting rights, representing approximately 4.3% of the outstanding voting rights.
• The sales occurred at various weighted average prices, with ADSs sold between $132.7347 and $140.9365, and Ordinary Shares sold between $144.2752 and $156.2041 (converted to USD where applicable).
• The Reporting Persons state that the shares were acquired for investment purposes and retain the right to adjust their investment strategy, including acquiring or disposing of further securities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as slightly negative due to the reported sales of a significant stake by a major investor, which could signal reduced confidence or a portfolio rebalancing.

Positives

• The Reporting Persons have provided clear disclosure of their recent share transactions.
• The sales were conducted in open market transactions, indicating normal market activity.
• The Reporting Persons retain the flexibility to adjust their investment strategy, which could be beneficial for future capital allocation.

Negatives

• Significant sales of Abivax shares by a major holder (Sofinnova Crossover I SLP) could be perceived negatively by the market.
• The reduction in ownership percentage from previous filings suggests a decreased conviction or a strategic shift by the Reporting Persons.

Risks

• The ongoing evaluation of investment alternatives by the Reporting Persons could lead to further sales of Abivax securities.
• Potential future proposals to management or the board of directors regarding strategic matters could introduce uncertainty.

Future Outlook

The Reporting Persons retain the right to change their investment intent, including acquiring additional securities or disposing of existing holdings. They may also engage in discussions with management or the board regarding strategic matters.

Industry Context

StockSavvy.ai notes that significant share sales by major investment funds can signal a shift in their outlook for a company or a broader market trend. This filing indicates a reduction in Sofinnova's stake in Abivax, which may prompt other investors to re-evaluate their positions.

Stakeholder Impact

• Shareholders may react to the reduction in ownership by a significant investor, potentially impacting share price.
• The market may interpret the sales as a signal regarding the company's future prospects, influencing investor sentiment.

Next Steps

• The Reporting Persons may continue to evaluate their investment and may engage in further transactions or discussions regarding Abivax's securities or strategy.

Key Dates

Recommendation

The filing primarily reports on past transactions (share sales) and does not contain new operational or strategic information that would warrant a strong buy or sell recommendation. The reduction in stake by Sofinnova is a point of consideration, but without further context on their motivations or Abivax's underlying performance, a 'hold' stance is prudent for seasoned investors.

Keywords

Schedule 13D, Abivax S.A., Sofinnova Crossover I SLP, Sofinnova Partners SAS, Shareholder, Securities Sale, American Depositary Shares, Ordinary Shares, SEC Filing, Investment